A detailed history of West End Advisors, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, West End Advisors, LLC holds 1 shares of REGN stock, worth $756. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1 -0.0%
Holding current value
$756
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

SELL
$883.2 - $1071.19 $883 - $1,071
-1 Reduced 50.0%
1 $1,000
Q3 2023

Oct 19, 2023

BUY
$692.45 - $844.37 $1,384 - $1,688
2 New
2 $1,000
Q2 2021

Jul 15, 2021

BUY
$472.8 - $558.54 $472 - $558
1 New
1 $558,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track West End Advisors, LLC Portfolio

Follow West End Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of West End Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on West End Advisors, LLC with notifications on news.